Astellas Pharma
¥2,245.00Change from previous close: −2.83%Absolute change: −¥65.50
Valuation
Data as of October 3, 2026
Valuation multiples
- Market cap
- ¥4.03T
- Enterprise value
- ¥4.37T
- P/E (trailing 12 months)
- 13.8
- Forward P/E
- 29.6
- PEG
- 0.37
- Price/book
- 2.07
- Price/sales
- 1.77
- EV/EBITDA
- 6.53
- EV/revenue
- 1.92
Profitability and growth
- Gross margin
- 80.8%
- Operating margin
- 28.9%
- Net margin
- 16.0%
- ROE
- 21.3%
- ROA
- 8.4%
- Revenue growth (year over year)
- 26.7%
- Earnings growth (year over year)
- 107.2%
Financial health
- Total cash
- ¥244.7B
- Total debt
- ¥589.87B
- Debt/equity
- 0.30
- Current ratio
- 1.20
- Quick ratio
- 0.88
Dividends
- Annual dividend per share
- ¥80.00
- Dividend yield
- 3.6%
- Payout ratio
- 48.1%
- Ex-dividend date
- March 30, 2027
Analysts and estimates
- Average price target
- ¥2,529.29
- Median price target
- ¥2,500.00
- High price target
- ¥3,100.00
- Low price target
- ¥2,000.00
- Analysts with a price target
- 14
- Consensus
- Buy
- Forward EPS
- ¥75.77
- EPS estimate, current year
- ¥213.37
Shares and trading
- Beta
- 0.09
- Average volume
- 6.32M
- Shares outstanding
- 1.79B
- Float
- 1.79B
- Institutional ownership
- 62.5%
- Insider ownership
- 0.1%